Targeting the immune checkpoint molecules CTLA-4, PD-1, and PD-L1 is revolutionizing clinical management for a variety of solid and hematological malignancies by generating durable anti-tumor immune responses (1, 2). Here, PDCD1 is linked to neoplasm.